Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Travere Therapeutics Inc (NQ: TVTX ) 9.530 +0.040 (+0.42%) Streaming Delayed Price Updated: 4:00 PM EDT, Jul 10, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings All News about Travere Therapeutics Inc < Previous 1 2 3 4 5 6 7 8 9 Next > 10 Health Care Stocks Whale Activity In Today's Session July 10, 2024 Via Benzinga Nvidia, Micron, Arlo Technologies And Other Big Stocks Moving Higher On Tuesday July 09, 2024 Via Benzinga Travere Therapeutics to Present at the H.C. Wainwright 3rd Annual Kidney Virtual Conference July 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) June 11, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Expert Outlook: Travere Therapeutics Through The Eyes Of 6 Analysts May 07, 2024 Via Benzinga Critical Insights From Travere Therapeutics Analyst Ratings: What You Need To Know April 17, 2024 Via Benzinga Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress May 09, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences May 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Peeling Back The Layers: Exploring Travere Therapeutics Through Analyst Insights March 13, 2024 Via Benzinga Deep Dive Into Travere Therapeutics Stock: Analyst Perspectives (7 Ratings) February 16, 2024 Via Benzinga Earnings Scheduled For February 15, 2024 February 15, 2024 Companies Reporting Before The Bell • Cognex (NASDAQ:CGNX) is estimated to report quarterly earnings at $0.10 per share on revenue of $188.59 million. Via Benzinga TVTX Stock Earnings: Travere Therapeutics Misses EPS, Misses Revenue for Q1 2024 May 06, 2024 TVTX stock results show that Travere Therapeutics missed analyst estimates for earnings per share and missed on revenue for the first quarter of 2024. Via InvestorPlace Travere Therapeutics Reports First Quarter 2024 Financial Results May 06, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report First Quarter 2024 Financial Results April 29, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy April 24, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Earnings Preview For Travere Therapeutics February 14, 2024 Via Benzinga Cracking The Code: Understanding Analyst Reviews For Travere Therapeutics January 18, 2024 Via Benzinga Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International April 04, 2024 Posters to be presented highlighting research investigating pegtibatinase as the first potential disease-modifying treatment for classical homocystinuria From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association April 03, 2024 Upcoming data presentations underscore the potential for FILSPARI to become a foundational treatment for IgAN and Travere’s leadership and commitment to innovation in rare kidney disease (RKD) From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) March 13, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN) March 11, 2024 Submission is based on 2-year confirmatory results from the Phase 3 PROTECT Study in which FILSPARI demonstrated a significant reduction in proteinuria, preservation of kidney function and a generally... From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at Upcoming Investor Conferences February 26, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy February 23, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results February 15, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results February 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the Guggenheim 6th Annual Biotechnology Conference February 01, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Announces Licensing Agreement with Renalys Pharma to Develop and Commercialize Sparsentan in Japan, South Korea, Taiwan, and Southeast Asian Nations January 25, 2024 Renalys expected to initiate registrational study in the second quarter of 2024 to support potential approval of sparsentan for IgA nephropathy in Japan From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics Provides Corporate Update and 2024 Outlook January 08, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire Travere Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference January 02, 2024 From Travere Therapeutics, Inc. Via GlobeNewswire < Previous 1 2 3 4 5 6 7 8 9 Next > Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.